Talecris Biotherapeutics, which manufactures plasma-derived protein therapies to treat both chronic and acute diseases and disorders, filed for an IPO on Friday. Morgan Stanley, Goldman Sachs and JP Morgan will manage the deal for the North Carolina-based company. Terms and timing have yet to be announced.
